BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30997878)

  • 1. An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
    Simsek FS; Arslan M; Dag Y
    Bosn J Basic Med Sci; 2019 May; 19(2):195-200. PubMed ID: 30997878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
    Simsek FS; Comak A; Asik M; Kuslu D; Balci TA; Ulutas H; Koroglu R; Kekilli E; Akatli A; Elmali F; Yalcin NC; Akyol H
    Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.
    Lim CH; Ahn TR; Moon SH; Cho YS; Choi JY; Kim BT; Lee KH
    Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of nodal involvement in non-small-cell lung cancer with 18F-FDG-PET/CT: mediastinal blood pool cut-off has the highest sensitivity and tumour SUVmax/2 has the highest specificity.
    Mallorie A; Goldring J; Patel A; Lim E; Wagner T
    Nucl Med Commun; 2017 Aug; 38(8):715-719. PubMed ID: 28658052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of different
    Anwar H; Vogl TJ; Abougabal MA; Grünwald F; Kleine P; Elrefaie S; Nour-Eldin NA
    Ann Nucl Med; 2018 Dec; 32(10):687-694. PubMed ID: 30219989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
    Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
    Lu Y; Xie D; Huang W; Gong H; Yu J
    Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.
    Stone WZ; Wymer DC; Canales BK
    J Endourol; 2014 Jan; 28(1):104-11. PubMed ID: 23927734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
    Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
    Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.